Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
复制标题
临床实践中乙型肝炎病毒感染对类风湿关节炎患者治疗反应的有害作用：病例对照研究
DOI：
10.1186/s13075-018-1548-5
复制
发表时间：
2018-05-02
影响因子：
4.9
通讯作者：
Dai L
中科院分区：
文献类型：
--
作者：
Chen YL;Lin JZ;Mo YQ;Ma JD;Li QH;Wang XY;Yang ZH;Yan T;Zheng DH;Dai L
BackgroundPrevious studies have revealed that hepatitis B virus (HBV) infection may be associated with rheumatoid arthritis (RA), while there are no further clinical studies regarding the role of HBV infection in RA progression during disease-modifying anti-rheumatic drug (DMARD) therapy. Here, we aimed to explore the influence of HBV infection on radiographic and clinical outcomes among patients with RA in a clinical practice setting.MethodsThirty-two consecutive patients with RA (Disease Activity Score 28-joint assessment based on C-reactive protein (DAS28-CRP) ≥2.6) with chronic HBV infection (CHB) were retrospectively recruited as the CHB group and 128 age-matched, sex-matched, and disease activity-matched contemporary patients with RA without CHB were included in the non-CHB group. Clinical data were collected at baseline and visits at month 1, 3, 6, and 12. The therapeutic target was defined as DAS28-CRP <2.6 in all patients or <3.2 in patients with long disease duration (>24 months). The primary outcome was the percentage of patients with one-year radiographic progression (a change in modified total Sharp score ≥0.5).ResultsCompared with the non-CHB group, a significantly higher percentage of patients with one-year radiographic progression was observed in the CHB group (53% vs. 17%,p< 0.001), with smaller proportions of patients achieving therapeutic target at month 6 and month 12 (53% vs. 82% and 53% vs. 75%, bothp< 0.05), remission at month 6 (DAS28-CRP <2.6, 50% vs. 72%,p= 0.039), and American College of Rheumatology (ACR)20/50 responses and good or moderate European League Against Rheumatism (EULAR) responses mainly at month 6 and 12 (allp< 0.05). Multivariate logistic regression analysis revealed that CHB status was significantly associated with one-year radiographic progression and failure to achieve therapeutic target within 6 months. HBV reactivation occurred in 34% of patients with CHB during one-year follow up, with two patients suffering hepatitis flare.ConclusionsHBV infection may play a deleterious role in radiographic and clinical outcomes in patients with RA, and HBV reactivation should be paid close attention during immunosuppressive therapy.
登录
查看更多内容
影响因子：
27.4
作者：
Takeuchi T;Yamanaka H;Ishiguro N;Miyasaka N;Mukai M;Matsubara T;Uchida S;Akama H;Kupper H;Arora V;Tanaka Y
通讯作者：
Tanaka Y
血清基质金属蛋白酶-3 连续升高 3 个月（相当于 6 个月）可预测类风湿关节炎一年的放射学进展：一项前瞻性队列研究
影响因子：
4.9
作者：
Ma JD;Wei XN;Zheng DH;Mo YQ;Chen LF;Zhang X;Li JH;Dai L
通讯作者：
Dai L
影响因子：
2.3
作者：
Mo YQ;Liang AQ;Ma JD;Chen LF;Zheng DH;Schumacher HR;Dai L
通讯作者：
Dai L
影响因子：
168.9
作者：
Schweitzer, Aparna;Horn, Johannes;Ott, Joerdis J.
通讯作者：
Ott, Joerdis J.
影响因子：
4.6
作者：
Ma JD;Zhou JJ;Zheng DH;Chen LF;Mo YQ;Wei XN;Yang LJ;Dai L
通讯作者：
Dai L